Bavarian Nordic updates phase III booster study plans, sets launch for August

The biotech firm aims to compare its Covid-19 vaccine candidate, ABNCoV2, with Pfizer/Biontech’s Comirnaty in a controlled, double-blind trial.
Photo: Sven Hoppe/AP/Ritzau Scanpix
Photo: Sven Hoppe/AP/Ritzau Scanpix
by christian bundgaard, translated by daniel pedersen

Bavarian Nordic has scheduled its phase III trial of its booster candidate against Covid-19, dubbed ABNCoV2, in August, according to a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading